Axsome Therapeutics is getting closer to becoming a profitable company, on a cash and earnings per share basis. An impressive 2nd quarter, with highlights below.
- On target to file a supplemental NDA for Alzheimer's Agitation 3rd quarter
- 150 million in second quarter revenue
- 303 million in cash
Chart below of Axsome Therapeutics, with corrections that the stock has endured the last few years. The average correction falls in the range of around 30%. Thank you for reading.
